Symptomatic vitreomacular adhesion treatment accepted for review by EMA

Article

Ocriplasmin, a treatment for symptomatic vitreomacular adhesion, has been accepted for review by the European Medicines Agency (EMA).

Ocriplasmin, a treatment for symptomatic vitreomacular adhesion, has been accepted for review by the European Medicines Agency (EMA).

The 2.5 mg/mL solution for injection, developed by ThromboGenics (Leuven, Belgium), prevents retinal distortion and further decreases in vision in VMA patients including macular hole. If ocriplasmin is approved it will be the first pharmacological treatment for VMA including macular hole. The solution will be available in the EU and the US.

The CEO of ThromboGenics, Dr Patrik De Haes, said, “The global ThromboGenics team is proud to have achieved the successful acceptance for review of the European MAA for ocriplasmin, a major corporate milestone. Ocriplasmin is also expected to be filed with the FDA in the US by the end of the year. If approved, ocriplasmin will be the first pharmacological treatment for a condition that is currently only treated via surgery, and only after the patient’s vision has significantly deteriorated."

ThromboGenics completed two Phase II clinical trials for ocrimplasmin. The drug is currently in clinical trials for further vitreoretinal conditions. Dr De Haes said, “We are continuing to make excellent progress in building our commercial organization to educate and support the retina specialist community, with the aim of ensuring ocriplasmin achieves its full therapeutic potential and delivers maximum benefit to patients.”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.